APA

Nimmanapalli R., Fuino L., Bali P., Gasparetto M., Glozak M., Tao J., Moscinski L., Smith C., Wu J., Jove R., Atadja P. & Bhalla K. (20030924). Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. : Cancer research.

Chicago

Nimmanapalli Ramadevi, Fuino Lianne, Bali Purva, Gasparetto Maura, Glozak Michele, Tao Jianguo, Moscinski Lynn, Smith Clayton, Wu Jie, Jove Richard, Atadja Peter and Bhalla Kapil. 20030924. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. : Cancer research.

Harvard

Nimmanapalli R., Fuino L., Bali P., Gasparetto M., Glozak M., Tao J., Moscinski L., Smith C., Wu J., Jove R., Atadja P. and Bhalla K. (20030924). Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. : Cancer research.

MLA

Nimmanapalli Ramadevi, Fuino Lianne, Bali Purva, Gasparetto Maura, Glozak Michele, Tao Jianguo, Moscinski Lynn, Smith Clayton, Wu Jie, Jove Richard, Atadja Peter and Bhalla Kapil. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. : Cancer research. 20030924.